GlassScriptPhysician profile
Michele B Kessler
NPI 1215161781
$5,611.02
in general payments reported to CMS, 2019-2025
28 companies · $1,781 in 2025
The $1,781 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $476 · 2022: $631 · 2023: $1,309 · 2024: $1,414 · 2025: $1,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,503.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,188.08 | 2021-2025 | Wegovy, Saxenda |
| Lilly USA, LLC | $921.47 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Mayne Pharma Commercial LLC | $647.26 | 2022-2025 | |
| Abbvie INC. | $545.68 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $427.69 | 2021-2025 | |
| Biogen, INC. | $292.42 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $280.31 | 2023-2025 | Myfembree |
| Pfizer INC. | $224.70 | 2021-2025 | |
| Astellas Pharma US INC | $177.55 | 2023-2025 | Veozah |
| Vivus LLC | $124.97 | 2023 | Qsymia |
| Evofem Biosciences, INC. | $114.39 | 2022-2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $103.16 | 2021-2025 | Slynd |
| Organon LLC | $89.48 | 2024-2025 | Nexplanon |
| Exact Sciences Corporation | $64.11 | 2023-2024 | Cologuard Collection Kit |
| Galderma Laboratories, L.P. | $55.82 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $46.30 | 2024-2025 | |
| Mylan Pharmaceuticals INC. | $39.85 | 2022 | |
| Sage Therapeutics, LLC | $39.24 | 2022 | |
| Hologic Sales and Service, LLC | $35.68 | 2022-2025 | Aptima |
| Myovant Sciences INC. | $32.11 | 2022 | |
| Therapeuticsmd, INC. | $26.17 | 2021 | |
| Dexcom, INC. | $24.42 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $22.83 | 2022 | |
| Agile Therapeutics, INC. | $22.44 | 2021 | |
| Sanofi Pasteur INC. | $18.71 | 2025 | |
| Scynexis, INC. | $18.33 | 2022 | |
| Avion Pharmaceuticals | $14.72 | 2023 | Balcoltra |
| Allergan, INC. | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.